Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ZYTIGA is substantial. |
Clinical Added Value
| moderate |
ZYTIGA provides a moderate improvement in actual benefit (level III) in terms of efficacy and tolerance in the treatment of metastatic castration-resistant prostate cancer which progresses during or after docetaxel therapy. |
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
4udYnUU48Pvh9Y16
